By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
“The Bad News Keeps Coming For MiMedx And Its New Auditor EY,” read the July 3, 2018, MarketWatch headline.
The publicly traded biopharma faced an accounting scandal involving three former executives (i.e., CEO, COO, and CFO), and consequently, would have to restate more than five years of financials. And more trouble would soon follow. It makes you wonder what type of person would want to take on leading a company that was facing such significant reputational challenges. How about 36-year biopharma veteran Tim Wright?